BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32231292)

  • 1. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients.
    McKenzie HS; Maishman T; Simmonds P; Durcan L; ; Eccles D; Copson E
    Br J Cancer; 2020 May; 122(11):1618-1629. PubMed ID: 32231292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Characterization of
    Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
    Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Malmgren JA; Mayer M; Atwood MK; Kaplan HG
    Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
    Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
    Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
    Seltzer S; Corrigan M; O'Reilly S
    Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival differences among women with de novo stage IV and relapsed breast cancer.
    Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
    Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Characterization of De Novo Metastatic Breast Cancer.
    Mullangi S; Vasan N
    Clin Breast Cancer; 2022 Feb; 22(2):98-102. PubMed ID: 34949553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
    Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
    Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
    Gaillard T; Carton M; Mailliez A; Desmoulins I; Mouret-Reynier MA; Petit T; Leheurteur M; Dieras V; Ferrero JM; Uwer L; Guiu S; Gonçalves A; Levy C; Debled M; Dalenc F; Patsouris A; Bachelot T; Eymard JC; Chevrot M; Conversano A; Robain M; Hequet D
    Eur J Cancer; 2021 Oct; 158():181-188. PubMed ID: 34689042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology of De Novo Metastatic Breast Cancer.
    Daily K; Douglas E; Romitti PA; Thomas A
    Clin Breast Cancer; 2021 Aug; 21(4):302-308. PubMed ID: 33750642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
    Müller V; Hein A; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Beckmann MW; Schneeweiss A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Meyer J; Wurmthaler LA; Kurbacher CM; Wuerstlein R; Untch M; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Fehm TN; Michel LL
    Eur J Cancer; 2022 Sep; 172():13-21. PubMed ID: 35728342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".
    Plichta JK; Thomas SM; Wang X; McDuff SGR; Kimmick G; Hwang ES
    Breast Cancer Res Treat; 2024 Jun; 205(2):333-347. PubMed ID: 38438700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
    Br J Cancer; 2015 Apr; 112(9):1445-51. PubMed ID: 25880008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
    Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
    Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?
    Rosier L; Wang Y; Lee JH; Daily K
    Breast Cancer Res Treat; 2022 Jan; 191(2):375-383. PubMed ID: 34787760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.
    Copson E; Eccles B; Maishman T; Gerty S; Stanton L; Cutress RI; Altman DG; Durcan L; Simmonds P; Lawrence G; Jones L; Bliss J; Eccles D;
    J Natl Cancer Inst; 2013 Jul; 105(13):978-88. PubMed ID: 23723422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
    Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.